Chemours (NYSE:CC) Posts Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Chemours (NYSE:CC) posted its quarterly earnings data on Monday. The specialty chemicals company reported $0.21 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05), FiscalAI reports. Chemours had a negative net margin of 2.64% and a positive return on equity of 76.52%. The company had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.53 billion. During the same quarter in the prior year, the business earned $0.40 EPS. Chemours’s revenue was up 3.0% compared to the same quarter last year.

Chemours Trading Down 7.4%

Shares of CC opened at $12.77 on Friday. The business’s 50-day moving average price is $14.02 and its 200 day moving average price is $18.23. The stock has a market capitalization of $1.92 billion, a P/E ratio of -12.51 and a beta of 1.47. Chemours has a 1-year low of $10.44 and a 1-year high of $28.67. The company has a current ratio of 1.81, a quick ratio of 0.88 and a debt-to-equity ratio of 24.25.

Chemours Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 15th. Investors of record on Monday, November 16th will be issued a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Monday, November 16th. Chemours’s payout ratio is presently -34.31%.

Insider Activity

In other news, CEO Denise Dignam acquired 3,378 shares of Chemours stock in a transaction on Tuesday, August 11th. The stock was bought at an average cost of $14.95 per share, with a total value of $50,501.10. Following the completion of the purchase, the chief executive officer owned 339,916 shares of the company’s stock, valued at $5,081,744.20. This represents a 1.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Calderon Gerardo Familiar bought 1,935 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was purchased at an average price of $15.53 per share, with a total value of $30,050.55. Following the completion of the acquisition, the insider owned 58,547 shares of the company’s stock, valued at approximately $909,234.91. This trade represents a 3.42% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.85% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

CC has been the subject of several research analyst reports. Barclays began coverage on Chemours in a report on Monday, October 12th. They issued an “equal weight” rating and a $16.00 price objective for the company. BMO Capital Markets lowered their target price on Chemours from $26.00 to $18.00 and set an “outperform” rating on the stock in a report on Thursday, August 13th. Zacks Research upgraded shares of Chemours from a “strong sell” rating to a “hold” rating in a research report on Thursday, September 10th. JPMorgan Chase & Co. cut their price target on shares of Chemours from $22.00 to $15.00 and set a “neutral” rating for the company in a report on Thursday, August 13th. Finally, Morgan Stanley set a $18.00 price target on shares of Chemours in a report on Monday, August 10th. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $17.45.

Chemours News Summary

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched Faizeon two-phase liquid-cooling solutions for AI data centers, which the company says can improve efficiency and reduce water use. The launch gives investors a potential growth opportunity in a fast-growing market. Article: CC Launches Faizeon Cooling Solutions to Meet AI Data Center Demand
• Neutral Sentiment: Analyst views remain mixed: Barclays maintained a Hold rating, UBS kept Neutral while trimming its price target to $15, and Truist lowered its target to $18 but retained a Buy rating. Article: Barclays Keeps Their Hold Rating on Chemours
• Negative Sentiment: Multiple law firms publicized a securities class action against Chemours, with a December 7 lead-plaintiff deadline. The lawsuit alleges the company misrepresented 2026 EBITDA guidance by not accounting for distributor pre-buying that shifted about $65 million in Opteon refrigerant sales from 2026 into 2025. The allegations have not been proven, but the case adds legal and reputational risk. Article: SueWallSt Reminds Shareholders of Lead Plaintiff Deadline
• Negative Sentiment: Recent quarterly results also provide a headwind: Chemours reported EPS of $0.21, below the $0.26 consensus and down from $0.40 a year earlier, despite revenue modestly exceeding estimates. The earnings shortfall and concerns about refrigerant demand may be contributing to investor caution.

Chemours Company Profile

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.